A Phase 3 interventional study of Saline (0.9%, sterile, for infusion) and low dose Methylprednisolone in Adenovirus Infections, Human, sponsored by Qingyuan Zhan. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Qingyuan Zhan · Phase 3, Interventional, and Treatment
Severe community-acquired pneumonia caused by adenovirus (hereafter referred to as severe adenovirus pneumonia) is one of the common forms of severe community-acquired pneumonia in immunocompetent adults. It predominantly affects young individuals, progresses rapidly, and is associated with a high incidence of respiratory failure and multiple organ dysfunction. At present, there is no effective antiviral therapy available in China, and the reported mortality rate ranges from 41.5% to 80%. How to effectively reduce the mortality of severe adenovirus pneumonia, on the basis of conventional supportive care, is crucial for improving the prognosis of critically ill patients and alleviating the burden on families and society. We are currently conducting an adaptive, randomized, open-label controlled trial aimed at reducing mortality in severe adenovirus pneumonia. The primary objective of this study is to evaluate the efficacy and safety of adjunctive corticosteroid therapy at different dosages, in addition to early standard supportive treatment, in lowering mortality among patients with severe adenovirus pneumonia.
104 studies on the registry are indexed under Adenoviridae Infections; 32 are open to participants now.
This study's planned enrollment of 262 is above the median of 36 across 80 interventional studies indexed under Adenoviridae Infections.
Browse Adenoviridae Infections studies →Qingyuan Zhan is the lead sponsor of 7 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Meeting at least one of the major diagnostic criteria for severe pneumonia:
(i) Requirement for endotracheal intubation and mechanical ventilation;
(ii) Septic shock requiring vasopressor therapy after adequate fluid resuscitation.
-Or simultaneously fulfilling three of the minor criteria:
(i) Respiratory rate ≥ 30 breaths/min;
(ii) PaO₂/FiO₂ ≤ 250 mmHg;
(iii) Multilobar infiltrates;
(iv) Altered mental status and/or disorientation;
(v) Blood urea nitrogen ≥ 20 mg/dL (7.12 mmol/L);
(vi) Leukopenia (white blood cell count \< 4 × 10⁹/L);
(vii) Thrombocytopenia (platelet count \< 100 × 10⁹/L);
(viii) Hypothermia (core temperature \< 36 °C);
(ix) Hypotension (systolic blood pressure \< 90 mmHg) requiring aggressive fluid resuscitation.
Exclusion Criteria:
Control group
Drug: Saline (0.9%, sterile, for infusion)
treated with low dose corticosteroids
Drug: low dose Methylprednisolone
treated with moderate dose corticosteroids
Drug: Moderate dose Methylprednisolone
Sailine as control
Methylprednisolone 0.5mg/kg ivgtt qd
Methylprednisolone 1.0mg/kg ivgtt qd
28-day all cause mortality
Time frame: 28 days from inclusion
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adenovirus Infections, Human
Qingyuan Zhan